Pneumocystis Pneumonia Diagnosis and Treatment

Introduction to Pneumocystis Pneumonia

Pneumocystis jirovecii is a fungus that specifically affects humans, and its cell wall composition contains β-D-glucan and nucleotide sequences more similar to fungi, which fundamentally shapes diagnostic and therapeutic approaches 1
The organism cannot be cultured in routine microbiology laboratories, making diagnosis dependent on direct visualization or molecular methods 1

The clinical presentation of Pneumocystis pneumonia is insidious with shortness of breath occurring early but relatively subtle findings on chest radiography 2
Dyspnea with hypoxemia is the earliest and most prominent symptom 3
Elevated serum lactate dehydrogenase (LDH) is characteristic and should trigger suspicion 4, 3
Findings on chest CT scan are often subtle initially despite significant respiratory symptoms 2

High-dose trimethoprim-sulfamethoxazole (TMP-SMX) at 15-20 mg/kg/day of the trimethoprim component is the first-line treatment and should be initiated immediately upon clinical suspicion 3
TMP-SMX dosing: 15-20 mg/kg/day of trimethoprim component (75-100 mg/kg/day sulfamethoxazole) divided every 6 hours 3
Treatment duration: 14-21 days depending on clinical response 3
If TMP-SMX cannot be used, clindamycin plus primaquine is the preferred alternative 3
Clindamycin: 600-900 mg IV every 6-8 hours (or 300-450 mg PO every 6 hours) 3
Primaquine: 15-30 mg base PO daily 3

Prophylaxis against Pneumocystis jirovecii is accomplished by 6-12 months of TMP-SMX (cotrimoxazole) 2
TMP-SMX is first choice for prophylaxis in all high-risk populations 6
Allogeneic transplant patients should receive prophylaxis from engraftment until end of immunosuppressive therapy or resolution of chronic GVHD, for at least 6 months 6

In HIV-infected children, PCP is most commonly diagnosed between 3-6 months of age with high mortality (35% died within 2 months) 7
Despite effective antimicrobial therapy, mortality from PCP among infants and children is high, with median survival of only 1-4 months from first episode 7

Never delay treatment while awaiting bronchoscopy or diagnostic confirmation 3
Always check G6PD levels before using primaquine or dapsone to prevent hemolytic crisis 3
Do not routinely use adjunctive corticosteroids in non-HIV cancer patients 3